Modality
ERT
MOA
DLL3 ADC
Target
LAG-3
Pathway
Amyloid
GBMOvarian CaObesity
Development Pipeline
Preclinical
~Jul 2018
→ ~Oct 2019
Phase 1
~Jan 2020
→ ~Apr 2021
Phase 2
Jul 2021
→ Dec 2031
Phase 2Current
NCT08521377
1,821 pts·GBM
2021-07→2031-12·Terminated
NCT08073228
778 pts·Obesity
2022-09→2027-10·Terminated
2,599 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-04-101w awayFast Track· Obesity
2027-10-011.5y awayPh3 Readout· Obesity
2031-12-055.7y awayPh3 Readout· GBM
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Termina…
P2/3
Termina…
Catalysts
Fast Track
2026-04-10 · 1w away
Obesity
Ph3 Readout
2027-10-01 · 1.5y away
Obesity
Ph3 Readout
2031-12-05 · 5.7y away
GBM
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08521377 | Phase 2/3 | GBM | Terminated | 1821 | HbA1c |
| NCT08073228 | Phase 2/3 | Obesity | Terminated | 778 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 | |
| STO-2663 | Stoke Ther | Approved | LAG-3 | |
| CVA-2171 | CureVac | Phase 1/2 | LAG-3 |